Researchers from Latigo Biotherapeutics and its clinical partners have reported positive Phase IIb data for its lead pipeline candidate, the non-opioid acute pain treatment LTG-001, which showed significantly greater pain reduction scores than placebo over 48 hours in patients with moderate or severe pain after abdominoplasty.
LTG-001 achieved the primary endpoint of the Phase IIb LTG-001-010 trial (NCT07102459) with high statistical significance by achieving better-than-placebo scores in the time-weighted sum of the pain-intensity difference (SPID) over the 48-hour treatment period (SPID48), based on the 0-10 range of scores of the Numeric Pain Rating Scale, with higher SPID48 values indicating greater pain reduction.
“The publication of these findings adds to the growing scientific understanding of non-opioid approaches to pain management and comes at a time when there is broad recognition of the need for additional treatment options in the context of the ongoing opioid…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
